138 related articles for article (PubMed ID: 38599972)
1. Anti-CD20 therapy for older patients with B-cell non-Hodgkin lymphoma in the context of epidemic normalization.
Zhang D; Xu S
Asian J Surg; 2024 Apr; ():. PubMed ID: 38599972
[No Abstract] [Full Text] [Related]
2. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.
Bannerji R; Arnason JE; Advani RH; Brown JR; Allan JN; Ansell SM; Barnes JA; O'Brien SM; Chávez JC; Duell J; Rosenwald A; Crombie JL; Ufkin M; Li J; Zhu M; Ambati SR; Chaudhry A; Lowy I; Topp MS
Lancet Haematol; 2022 May; 9(5):e327-e339. PubMed ID: 35366963
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD20 antibodies and bendamustine attenuate humoral immunity to COVID-19 vaccination in patients with B-cell non-Hodgkin lymphoma.
Ishio T; Tsukamoto S; Yokoyama E; Izumiyama K; Saito M; Muraki H; Kobayashi M; Mori A; Morioka M; Kondo T
Ann Hematol; 2023 Jun; 102(6):1421-1431. PubMed ID: 37041299
[TBL] [Abstract][Full Text] [Related]
4. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
5. CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.
Pijuan L; Vicioso L; Bellosillo B; Ferrer MD; Baró T; Pedro C; Lloreta-Trull J; Munné A; Serrano S
Am J Surg Pathol; 2005 Oct; 29(10):1399-403. PubMed ID: 16160485
[TBL] [Abstract][Full Text] [Related]
6. CD20-Negative Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A 20-Year Consecutive Case Series From a Tertiary Cancer Center.
Menke JR; Spinner MA; Natkunam Y; Warnke RA; Advani RH; Gratzinger DA
Arch Pathol Lab Med; 2021 Jun; 145(6):753-758. PubMed ID: 32991677
[TBL] [Abstract][Full Text] [Related]
7. CD20 Over-Expression in Hodgkin-Reed-Sternberg Cells of Classical Hodgkin Lymphoma: the Neglected Quest.
Benharroch D; Nalbandyan K; Lazarev I
J Cancer; 2015; 6(11):1155-9. PubMed ID: 26516364
[TBL] [Abstract][Full Text] [Related]
8. Expression of B-cell markers in classical hodgkin lymphoma: a tissue microarray analysis of 330 cases.
Tzankov A; Zimpfer A; Pehrs AC; Lugli A; Went P; Maurer R; Pileri S; Dirnhofer S
Mod Pathol; 2003 Nov; 16(11):1141-7. PubMed ID: 14614054
[TBL] [Abstract][Full Text] [Related]
9. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122
[TBL] [Abstract][Full Text] [Related]
10. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD20 antibody treatment of non-Hodgkin lymphomas.
Engelhard M
Clin Immunol; 2016 Nov; 172():101-104. PubMed ID: 27531574
[TBL] [Abstract][Full Text] [Related]
12. Determination of cyclin D1 and CD20 mRNA levels by real-time quantitative RT-PCR from archival tissue sections of mantle cell lymphoma and other non-Hodgkin's lymphomas.
Thomázy VA; Luthra R; Uthman MO; Davies PJ; Medeiros LJ
J Mol Diagn; 2002 Nov; 4(4):201-8. PubMed ID: 12411587
[TBL] [Abstract][Full Text] [Related]
13. The value of anti-pax-5 immunostaining in routinely fixed and paraffin-embedded sections: a novel pan pre-B and B-cell marker.
Torlakovic E; Torlakovic G; Nguyen PL; Brunning RD; Delabie J
Am J Surg Pathol; 2002 Oct; 26(10):1343-50. PubMed ID: 12360049
[TBL] [Abstract][Full Text] [Related]
14. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.
Hutchings M; Mous R; Clausen MR; Johnson P; Linton KM; Chamuleau MED; Lewis DJ; Sureda Balari A; Cunningham D; Oliveri RS; Elliott B; DeMarco D; Azaryan A; Chiu C; Li T; Chen KM; Ahmadi T; Lugtenburg PJ
Lancet; 2021 Sep; 398(10306):1157-1169. PubMed ID: 34508654
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD20 treatment for B-cell malignancies: current status and future directions.
Klein C; Jamois C; Nielsen T
Expert Opin Biol Ther; 2021 Feb; 21(2):161-181. PubMed ID: 32933335
[TBL] [Abstract][Full Text] [Related]
16. Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma.
Ravi D; Sarkar S; Purvey S; Passero F; Beheshti A; Chen Y; Mokhtar M; David K; Konry T; Evens AM
Leukemia; 2020 May; 34(5):1291-1304. PubMed ID: 31772298
[TBL] [Abstract][Full Text] [Related]
17. Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice.
Horikawa M; Minard-Colin V; Matsushita T; Tedder TF
J Clin Invest; 2011 Nov; 121(11):4268-80. PubMed ID: 22019587
[TBL] [Abstract][Full Text] [Related]
18. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
[TBL] [Abstract][Full Text] [Related]
19. B cell subsets reconstitution and immunoglobulin levels in children and adolescents with B non-Hodgkin lymphoma after treatment with single anti CD20 agent dose included in chemotherapeutic protocols: single center experience and review of the literature.
Hlavackova E; Krenova Z; Kerekes A; Slanina P; Vlkova M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2023 May; ():. PubMed ID: 37227099
[TBL] [Abstract][Full Text] [Related]
20. Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice.
Chu Y; Hochberg J; Yahr A; Ayello J; van de Ven C; Barth M; Czuczman M; Cairo MS
Cancer Immunol Res; 2015 Apr; 3(4):333-44. PubMed ID: 25492700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
